Welcome to our dedicated page for REGENERON PHARMACEUTICALS SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REGENERON PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REGENERON PHARMACEUTICALS's regulatory disclosures and financial reporting.
REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025, indicating it was scheduled in advance. Following this transaction, Ryan directly holds 17,303 shares of Regeneron common stock.
Regeneron Pharmaceuticals, Inc. expects to record an acquired in-process research and development charge of approximately $127 million on a pre-tax basis in its second quarter 2026 results. This charge comes from up-front and opt-in payments tied to collaboration and licensing agreements.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the quarter by about $1.00. Regeneron notes these results are preliminary and subject to completion of financial closing procedures, and emphasizes that it does not forecast such charges because their timing and size are uncertain.
Regeneron Pharmaceuticals filed a Form 144 notice for the proposed sale of 400 shares of Common Stock through J.P. Morgan Securities LLC at its New York address. The filing also records a prior sale of 100 shares on 05/01/2026 for $70,523.79.
Regeneron Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. Shareholders elected five Class II directors to serve until the 2027 annual meeting, with each nominee receiving substantially more votes "For" than "Against."
Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,503,788 votes For and 6,443,958 Against. In addition, the advisory resolution approving executive compensation received 96,469,374 votes For and 6,898,268 Against, with 5,543,411 broker non-votes.
Regeneron Pharmaceuticals, Inc. filed a Form 13F reporting institutional holdings as of the filing, listing 2 information-table entries with a Form 13F Information Table Value Total of $47,884,476. The report was signed by Leonard Brooks, Senior Vice President, Treasurer, on 05-08-2026.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock in multiple open-market trades on May 1, 2026. The shares were sold at prices generally between about $701 and $714 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025. After these planned sales, he continues to hold a direct equity stake in the company.
Regeneron Pharmaceuticals Inc disclosure: Vanguard Capital Management reported beneficial ownership of 7,660,810 shares of Common Stock, representing 7.37% of the class. The filing shows sole voting power for 1,005,897 shares and sole dispositive power over 7,660,810 shares.
The filing states these holdings include shares held for Vanguard funds and managed accounts and is signed by Vanguard Capital Management's Head of Global Fund Administration on 04/30/2026.
Regeneron Pharmaceuticals reported strong first quarter 2026 results, with total revenues rising 19% to $3.6 billion from $3.0 billion a year earlier, driven by Dupixent and oncology growth. GAAP net income declined 10% to $727 million as higher R&D, IPR&D and manufacturing costs weighed on margins, while non-GAAP net income increased 12% to $1.04 billion and diluted non‑GAAP EPS grew 15% to $9.47.
Dupixent global net sales recorded by Sanofi rose 33% to $4.9 billion, and Libtayo global net sales climbed 54% to $438 million. EYLEA HD U.S. net sales jumped 52% to $468 million, but combined U.S. EYLEA HD and EYLEA net sales fell 10% to $941 million amid competitive pressures and patient transition to EYLEA HD.
The quarter featured multiple regulatory wins, including FDA and EC approvals expanding Dupixent indications, extended EYLEA HD dosing intervals, and accelerated FDA approval of Otarmeni, which Regeneron will provide for free in the U.S. The company repurchased $803 million of stock, authorized a new $3.0 billion buyback, and declared a $0.94 per‑share dividend. Guidance for 2026 largely held, though GAAP gross margin on net product sales was trimmed to 77–78% due to a temporary manufacturing interruption in Ireland.